Protective immunity and safety of a genetically modified influenza virus vaccine
AuthorsBarbosa, Rafael Polidoro Alves
Salgado, Ana Paula Carneiro
Garcia, Cristiana Couto
Filho, Bruno Galvao
Goncalves, Ana Paula de Faria Paula de Faria
Lima, Braulio Henrique Freire
Lopes, Gabriel Augusto Oliveira
Rachid, Milene Alvarenga
Peixoto, Andiara Cristina Cardoso
de Oliveira, Danilo Bretas
Ataide, Marco Antonio
Zirke, Carla Aparecida
Cotrim, Tatiane Marques
Costa, Erica Azevedo
Almeida, Gabriel Magno de Freitas
Russo, Remo Castro
Gazzinelli, Ricardo T.
Vieira Machado, Alexandre de Magalhaes
UMass Chan AffiliationsDepartment of Medicine, Division of Infectious Diseases and Immunology
MetadataShow full item record
AbstractRecombinant influenza viruses are promising viral platforms to be used as antigen delivery vectors. To this aim, one of the most promising approaches consists of generating recombinant viruses harboring partially truncated neuraminidase (NA) segments. To date, all studies have pointed to safety and usefulness of this viral platform. However, some aspects of the inflammatory and immune responses triggered by those recombinant viruses and their safety to immunocompromised hosts remained to be elucidated. In the present study, we generated a recombinant influenza virus harboring a truncated NA segment (vNA-Delta) and evaluated the innate and inflammatory responses and the safety of this recombinant virus in wild type or knock-out (KO) mice with impaired innate (Myd88 -/-) or acquired (RAG -/-) immune responses. Infection using truncated neuraminidase influenza virus was harmless regarding lung and systemic inflammatory response in wild type mice and was highly attenuated in KO mice. We also demonstrated that vNA-Delta infection does not induce unbalanced cytokine production that strongly contributes to lung damage in infected mice. In addition, the recombinant influenza virus was able to trigger both local and systemic virus-specific humoral and CD8+ T cellular immune responses which protected immunized mice against the challenge with a lethal dose of homologous A/PR8/34 influenza virus. Taken together, our findings suggest and reinforce the safety of using NA deleted influenza viruses as antigen delivery vectors against human or veterinary pathogens.
SourcePLoS One. 2014 Jun 13;9(6):e98685. doi: 10.1371/journal.pone.0098685. eCollection 2014. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/30182
Related ResourcesLink to Article in PubMed
Rights© 2014 Barbosa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Except where otherwise noted, this item's license is described as © 2014 Barbosa et al. This is an open-access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.